Rein Therapeutics (RNTX)
Develops peptide candidates for pulmonary fibrosis and related lung diseases.
Something off on this page? Send us feedback.
Develops peptide candidates for orphan pulmonary and fibrosis indications. Its lead program, LTI-03, is in a Phase 2 trial for idiopathic pulmonary fibrosis, while LTI-01 has completed earlier studies for loculated pleural effusions.
Develops peptide therapies for orphan pulmonary and fibrosis indications. Its lead candidate, LTI-03, is being evaluated in the randomized, placebo-controlled Phase 2 RENEW trial for idiopathic pulmonary fibrosis; enrollment spans planned sites in five countries. LTI-01, a second candidate for loculated pleural effusions, has completed earlier Phase 1b and Phase 2a studies.
Clinical execution is centered on LTI-03 following the 2023 acquisition of Lung Therapeutics and the 2025 Rein rebrand. The company’s stated use of recent offering proceeds includes completing the LTI-03 trial, alongside clinical, manufacturing, and regulatory activities. Its present business therefore depends on advancing a small, pulmonary-focused clinical pipeline through development.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jan 21, 2026 | Brookline Capital | Downgrade | ||
| Nov 3, 2025 | Loop Capital Markets | Target | Target: — | Target: $6 |
| Aug 19, 2025 | Brookline Capital | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $40.6M · Total debt $0 · Total assets $66.0M · Shareholders' equity $10.2M
- Revenue
- $0
- Operating income
- −$6.1M
- Net income
- −$6.4M
No dividends on record.
| Institutions | 47.34% | 40.84M shares | |
|---|---|---|---|
| 59 holders · as of Jun 30, 2026 | |||
| Insiders | 0.10% | 89.6K shares | |
| 2 holders · as of May 28, 2026 | |||
| Strategic holders | 5.51% | 4.75M shares | |
| 1 holder · as of May 8, 2026 | |||
| Other | 47.05% | 40.59M shares | |
| remainder | |||
86.27M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (86.27M in the company's Sep 23, 2026 report, 27.96M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Voss Capital, LPInstitution | 6.10% | 5.26M | as of Jun 30, 2026 |
Cable Car Capital LLCInstitution | 6.02% | 5.20M | as of Jun 30, 2026 |
Funicular Funds, LPInstitution | 6.02% | 5.20M | filed May 7, 2026 |
Lynwood Capital Management Inc.Strategic | 5.51% | 4.75M | filed May 8, 2026 |
Adar1 Capital Management, LLCInstitution | 5.22% | 4.50M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 21, 2026 | Josef H. von Rickenbach | director | +3,420 | $1.04 |
| May 22, 2026 | Josef H. von Rickenbach | director | +15,950 | $1.05 |
| May 26, 2026 | Josef H. von Rickenbach | director | +23,190 | $1.06 |
| May 27, 2026 | Josef H. von Rickenbach | director | +4,500 | $1.07 |
| Apr 30, 2026 | James Brian Windsor | director, officer: See Remarks | +25,000 | $1.00 |
- United Therapeutics
Late-stage inhaled Tyvaso program targets IPF lung function.
- Bristol-Myers Squibb
Phase 3 admilparant program addresses IPF and lung-function decline.
- Contineum Therapeutics
Global Phase 2 PIPE-791 trial competes for IPF development and sites.
- Trevi Therapeutics
Planned pivotal Haduvio trials target chronic cough in IPF.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Rein Therapeutics | $0.7700 | −3.11% | $22.2M | — | — | — | — |
| United Therapeutics | $489.47 | −1.63% | $21.12B | 17.8 | 18.9 | 6.7 | −1.9% |
| Bristol-Myers Squibb | $61.59 | −1.06% | $127.16B | 13.7 | 9.6 | 2.6 | +5.7% |
| Contineum Therapeutics | $13.03 | −2.79% | $504.1M | — | — | — | — |
| Trevi Therapeutics | $14.48 | −4.98% | $2.16B | — | — | — | — |
| Median | 15.8 | 14.3 | 4.6 | +1.9% |